StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Free Report) in a research report released on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.
RedHill Biopharma Stock Performance
RDHL stock opened at $5.72 on Thursday. The firm’s 50-day moving average is $6.89 and its two-hundred day moving average is $64.88. RedHill Biopharma has a 52 week low of $5.41 and a 52 week high of $31.50.
Institutional Trading of RedHill Biopharma
A hedge fund recently bought a new stake in RedHill Biopharma stock. GAMMA Investing LLC bought a new position in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned 0.40% of RedHill Biopharma as of its most recent SEC filing. 7.20% of the stock is currently owned by institutional investors.
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
Read More
- Five stocks we like better than RedHill Biopharma
- Using the MarketBeat Dividend Tax Calculator
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- What Are Dividend Achievers? An Introduction
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- 3 Tickers Leading a Meme Stock Revival
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
